Back to Search
DR. TIMO WILLIAM HAKKARAINEN M.D.
M.D.
Surgery Physician
NPI: 1568604304IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
MC-2858(ID)21144(ND)232628(AK)MD60224925(WA)
Education
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Class of 2009
Research & Publications (20)
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
PMID 19440223·Gene Ther·2009
7-preclinical
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
PMID 19672857·Int J Cancer·2009
7-preclinical
Extended release of adenovirus from silica implants in vitro and in vivo.
PMID 18754041·Gene Ther·2009
4-observational
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
PMID 18338835·J Gene Med·2008
4-observational
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
PMID 18632604·Cancer Res·2008
7-preclinical
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
PMID 18401431·Gene Ther·2008
7-preclinical
Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
PMID 18922906·Cancer Res·2008
7-preclinical
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.
PMID 18799589·J Virol·2008
8-other
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
PMID 17611584·Gene Ther·2007
7-preclinical
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
PMID 17938266·Mol Cancer Ther·2007
7-preclinical
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
PMID 17315187·Int J Cancer·2007
7-preclinical
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.
PMID 17848962·Mol Ther·2007
7-preclinical
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
PMID 17308070·Mol Cancer Ther·2007
7-preclinical
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
PMID 16900223·Gene Ther·2007
7-preclinical
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
PMID 17377596·Gene Ther·2007
7-preclinical
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
PMID 17604566·Hum Gene Ther·2007
7-preclinical
Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines.
PMID 17191255·J Gene Med·2007
7-preclinical
A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
PMID 16964432·Int J Mol Med·2006
7-preclinical
In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition.
PMID 16385565·Int J Cancer·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via INNOVIS HEALTH LLC · 4 locations total
- Address
- 3000 32ND AVE S
FARGO, ND 58103 - Phone
- (701) 364-8000
Quick Facts
- NPI
- 1568604304
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 4
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile